Tesi and Debiopharm in $10m series-B for BC Platforms
Finnish VC investor Tesi and Swiss biopharmaceutical group Debiopharm have invested in a $10m series-B funding round for Basel-based genomic data management company BC Platforms.
More on DACH
415 Capital holds first close for maiden fund
Medtech-focused VC fund will target startups involved in the treatment of cardiovascular diseases
Capza appoints Abensour as head of investor relations
GP also appoints Stefan Arneth from MEAG as sales manager for Germany, Austria and Switzerland
DACH VCs introduce sustainability clause
VCs and their portfolio companies will commit via a term sheet and shareholder agreement clause
Project A leads $12m round for Anyline
Software developer, which works on an AI-backed optical character recognition program, is opening a US-based subsidiary
Latest News
Ergon Capital Partners to back CompaNanny
Belgian GP plans to back the company, according to a document by the Dutch competition authority
Eight Roads et al. in €42.6m series-B for Funnel
Fresh capital will be used to accelerate Funnel's operations in the US and invest in its technical teams
Omnes backs Opportunity LBO
MACSF co-invested with the GP in a spin-off from Vocalcom Group, an Apax France portfolio company
Inflexion acquires Marston minority stake
Marston is a judicial services group, which recovers funds on behalf of taxpayers and businesses